 Elena Ambrogini
Concepts (237)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Density | 7 | 2023 | 379 | 1.640 |
Why?
| | Osteogenesis | 7 | 2023 | 352 | 1.640 |
Why?
| | Osteoblasts | 12 | 2023 | 450 | 1.580 |
Why?
| | Phospholipids | 2 | 2021 | 57 | 1.490 |
Why?
| | Bone and Bones | 7 | 2023 | 469 | 1.060 |
Why?
| | Scavenger Receptors, Class B | 2 | 2023 | 10 | 1.050 |
Why?
| | Bone Diseases, Metabolic | 2 | 2023 | 74 | 0.940 |
Why?
| | Osteoporosis | 4 | 2020 | 146 | 0.810 |
Why?
| | Forkhead Transcription Factors | 5 | 2016 | 112 | 0.710 |
Why?
| | Hyperparathyroidism, Primary | 6 | 2009 | 35 | 0.670 |
Why?
| | Mice | 18 | 2024 | 5739 | 0.640 |
Why?
| | Immunoglobulin M | 1 | 2018 | 52 | 0.620 |
Why?
| | Single-Chain Antibodies | 1 | 2018 | 21 | 0.620 |
Why?
| | Aging | 3 | 2021 | 687 | 0.620 |
Why?
| | Epitopes | 1 | 2018 | 59 | 0.620 |
Why?
| | Animals | 23 | 2024 | 13187 | 0.560 |
Why?
| | Oxidative Stress | 6 | 2011 | 770 | 0.540 |
Why?
| | Mice, Knockout | 5 | 2022 | 841 | 0.500 |
Why?
| | Mice, Transgenic | 4 | 2021 | 555 | 0.420 |
Why?
| | Bone Resorption | 5 | 2023 | 304 | 0.350 |
Why?
| | Osteoclasts | 5 | 2023 | 425 | 0.350 |
Why?
| | Parathyroid Neoplasms | 6 | 2008 | 26 | 0.340 |
Why?
| | Oxidation-Reduction | 3 | 2020 | 322 | 0.330 |
Why?
| | Estrogens | 5 | 2012 | 227 | 0.310 |
Why?
| | Wnt Signaling Pathway | 3 | 2013 | 92 | 0.300 |
Why?
| | Female | 27 | 2022 | 26472 | 0.290 |
Why?
| | Estrogen Receptor alpha | 3 | 2012 | 89 | 0.270 |
Why?
| | Signal Transduction | 4 | 2024 | 1618 | 0.270 |
Why?
| | Cells, Cultured | 6 | 2018 | 1573 | 0.270 |
Why?
| | Gene Deletion | 3 | 2016 | 266 | 0.260 |
Why?
| | Stem Cells | 3 | 2016 | 171 | 0.250 |
Why?
| | Tumor Suppressor Proteins | 5 | 2008 | 128 | 0.240 |
Why?
| | Osteoporosis, Postmenopausal | 1 | 2005 | 32 | 0.240 |
Why?
| | Apoptosis | 7 | 2011 | 1101 | 0.240 |
Why?
| | Male | 18 | 2022 | 25241 | 0.240 |
Why?
| | Mice, Inbred C57BL | 6 | 2018 | 1816 | 0.240 |
Why?
| | Chemokine CXCL12 | 1 | 2024 | 32 | 0.240 |
Why?
| | Autoimmune Diseases | 1 | 2005 | 101 | 0.230 |
Why?
| | Hyperparathyroidism | 4 | 2004 | 31 | 0.220 |
Why?
| | Cell Differentiation | 4 | 2020 | 651 | 0.220 |
Why?
| | Mechanotransduction, Cellular | 1 | 2023 | 36 | 0.210 |
Why?
| | Tumor Microenvironment | 1 | 2024 | 212 | 0.210 |
Why?
| | Adipogenesis | 2 | 2020 | 51 | 0.210 |
Why?
| | T-Lymphocytes | 1 | 2005 | 338 | 0.210 |
Why?
| | Parathyroidectomy | 3 | 2009 | 45 | 0.210 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2024 | 308 | 0.210 |
Why?
| | Receptors, Scavenger | 1 | 2022 | 29 | 0.200 |
Why?
| | Parathyroid Hormone | 3 | 2010 | 147 | 0.200 |
Why?
| | Cell Proliferation | 5 | 2018 | 1007 | 0.190 |
Why?
| | Hypothyroidism | 2 | 2021 | 54 | 0.190 |
Why?
| | Osteocytes | 1 | 2023 | 207 | 0.180 |
Why?
| | Thyroxine | 1 | 2021 | 47 | 0.180 |
Why?
| | Antibodies, Neutralizing | 1 | 2020 | 64 | 0.180 |
Why?
| | Reactive Oxygen Species | 4 | 2014 | 408 | 0.170 |
Why?
| | Adenoma | 6 | 2008 | 110 | 0.160 |
Why?
| | Shc Signaling Adaptor Proteins | 4 | 2011 | 20 | 0.160 |
Why?
| | Hypertension | 1 | 2022 | 533 | 0.140 |
Why?
| | Lipoproteins, LDL | 1 | 2018 | 170 | 0.140 |
Why?
| | Glucocorticoids | 2 | 2011 | 219 | 0.140 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2011 | 388 | 0.140 |
Why?
| | Androgens | 2 | 2022 | 69 | 0.140 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2021 | 488 | 0.140 |
Why?
| | Pregnancy Complications | 1 | 2021 | 382 | 0.140 |
Why?
| | Hydrogen Peroxide | 2 | 2014 | 115 | 0.130 |
Why?
| | Calcium | 2 | 2008 | 396 | 0.130 |
Why?
| | Diet, High-Fat | 1 | 2018 | 222 | 0.130 |
Why?
| | Aged | 9 | 2023 | 9310 | 0.130 |
Why?
| | Wnt Proteins | 3 | 2011 | 100 | 0.130 |
Why?
| | Humans | 23 | 2024 | 49974 | 0.130 |
Why?
| | Gene Expression Regulation, Enzymologic | 2 | 2014 | 181 | 0.130 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2016 | 129 | 0.130 |
Why?
| | Middle Aged | 12 | 2021 | 12069 | 0.120 |
Why?
| | Catalase | 1 | 2014 | 67 | 0.120 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2016 | 198 | 0.120 |
Why?
| | Cell Cycle Proteins | 2 | 2013 | 166 | 0.110 |
Why?
| | Periosteum | 1 | 2012 | 26 | 0.110 |
Why?
| | Receptors, Calcium-Sensing | 2 | 2008 | 4 | 0.100 |
Why?
| | Prednisolone | 1 | 2011 | 55 | 0.100 |
Why?
| | Osteoprotegerin | 2 | 2023 | 52 | 0.090 |
Why?
| | Parathyroid Glands | 2 | 2007 | 20 | 0.090 |
Why?
| | Protein Kinase C | 1 | 2010 | 71 | 0.090 |
Why?
| | Sulfaphenazole | 1 | 2009 | 4 | 0.090 |
Why?
| | Transgenes | 1 | 2010 | 55 | 0.090 |
Why?
| | Multiple Myeloma | 1 | 2024 | 2929 | 0.090 |
Why?
| | Family Health | 2 | 2008 | 80 | 0.090 |
Why?
| | Dexamethasone | 1 | 2011 | 430 | 0.080 |
Why?
| | PPAR gamma | 1 | 2009 | 73 | 0.080 |
Why?
| | Spinal Fractures | 1 | 2009 | 38 | 0.080 |
Why?
| | NF-kappa B | 1 | 2010 | 314 | 0.080 |
Why?
| | Hypercalcemia | 1 | 2008 | 33 | 0.080 |
Why?
| | Postmenopause | 1 | 2009 | 100 | 0.080 |
Why?
| | Lipid Metabolism | 1 | 2009 | 175 | 0.080 |
Why?
| | Estradiol | 1 | 2010 | 225 | 0.080 |
Why?
| | Germ-Line Mutation | 2 | 2007 | 61 | 0.080 |
Why?
| | Up-Regulation | 1 | 2010 | 452 | 0.080 |
Why?
| | Nitric Oxide | 1 | 2009 | 253 | 0.080 |
Why?
| | Aged, 80 and over | 3 | 2022 | 3129 | 0.070 |
Why?
| | Endpoint Determination | 1 | 2007 | 24 | 0.070 |
Why?
| | Adult | 11 | 2021 | 13236 | 0.070 |
Why?
| | Absorptiometry, Photon | 1 | 2007 | 154 | 0.070 |
Why?
| | Spine | 1 | 2007 | 94 | 0.070 |
Why?
| | Interpersonal Relations | 1 | 2007 | 105 | 0.070 |
Why?
| | Data Interpretation, Statistical | 1 | 2007 | 158 | 0.070 |
Why?
| | Disease Models, Animal | 2 | 2016 | 1455 | 0.070 |
Why?
| | Phenotype | 2 | 2013 | 729 | 0.060 |
Why?
| | X-Ray Microtomography | 2 | 2016 | 77 | 0.060 |
Why?
| | Loss of Heterozygosity | 4 | 2007 | 77 | 0.060 |
Why?
| | Major Histocompatibility Complex | 1 | 2005 | 11 | 0.060 |
Why?
| | Graves Disease | 1 | 2005 | 18 | 0.060 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2005 | 37 | 0.060 |
Why?
| | Hepatitis, Autoimmune | 1 | 2005 | 26 | 0.060 |
Why?
| | Infarction | 1 | 2004 | 14 | 0.060 |
Why?
| | Femur | 2 | 2016 | 133 | 0.060 |
Why?
| | Gene Expression Regulation | 1 | 2009 | 976 | 0.060 |
Why?
| | Lymphocyte Activation | 1 | 2005 | 172 | 0.060 |
Why?
| | Echocardiography | 1 | 2007 | 378 | 0.060 |
Why?
| | Transcription Factors | 3 | 2013 | 561 | 0.060 |
Why?
| | Transforming Growth Factor beta | 1 | 2005 | 144 | 0.060 |
Why?
| | Congenital Hypothyroidism | 1 | 2003 | 4 | 0.060 |
Why?
| | Symporters | 1 | 2003 | 17 | 0.060 |
Why?
| | Ion Channels | 1 | 2023 | 72 | 0.050 |
Why?
| | Multiple Endocrine Neoplasia Type 1 | 1 | 2002 | 4 | 0.050 |
Why?
| | Immunization, Passive | 1 | 2022 | 29 | 0.050 |
Why?
| | Proteins | 1 | 2004 | 342 | 0.050 |
Why?
| | Quality of Life | 1 | 2007 | 836 | 0.050 |
Why?
| | Prospective Studies | 1 | 2007 | 2364 | 0.050 |
Why?
| | Treatment Outcome | 2 | 2022 | 5141 | 0.050 |
Why?
| | Arachidonate 12-Lipoxygenase | 2 | 2010 | 13 | 0.040 |
Why?
| | Arachidonate 15-Lipoxygenase | 2 | 2010 | 13 | 0.040 |
Why?
| | Gene Knock-In Techniques | 2 | 2010 | 22 | 0.040 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2024 | 828 | 0.040 |
Why?
| | Multienzyme Complexes | 2 | 2010 | 34 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2024 | 1403 | 0.040 |
Why?
| | Patient Safety | 1 | 2021 | 102 | 0.040 |
Why?
| | Enzyme Activation | 2 | 2010 | 276 | 0.040 |
Why?
| | Oxygen | 1 | 2022 | 326 | 0.040 |
Why?
| | Phosphorylation | 2 | 2010 | 535 | 0.040 |
Why?
| | Transcription, Genetic | 2 | 2010 | 369 | 0.040 |
Why?
| | Patient Education as Topic | 1 | 2021 | 302 | 0.040 |
Why?
| | Risk Factors | 2 | 2021 | 3613 | 0.040 |
Why?
| | Hospitalization | 1 | 2022 | 652 | 0.040 |
Why?
| | Mutation, Missense | 2 | 2008 | 105 | 0.040 |
Why?
| | Immunohistochemistry | 3 | 2007 | 973 | 0.040 |
Why?
| | Age Factors | 1 | 2020 | 1087 | 0.040 |
Why?
| | Cell Line | 2 | 2010 | 1000 | 0.040 |
Why?
| | Integrases | 1 | 2016 | 43 | 0.030 |
Why?
| | COS Cells | 2 | 2008 | 74 | 0.030 |
Why?
| | Carcinoma | 2 | 2008 | 138 | 0.030 |
Why?
| | Cell Lineage | 1 | 2016 | 83 | 0.030 |
Why?
| | Risk Assessment | 1 | 2021 | 1259 | 0.030 |
Why?
| | Organ Size | 1 | 2016 | 226 | 0.030 |
Why?
| | Proto-Oncogene Proteins | 2 | 2007 | 149 | 0.030 |
Why?
| | Sensitivity and Specificity | 2 | 2009 | 861 | 0.030 |
Why?
| | Transfection | 2 | 2008 | 354 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2021 | 1557 | 0.030 |
Why?
| | Arkansas | 1 | 2021 | 1977 | 0.030 |
Why?
| | Recurrence | 2 | 2007 | 652 | 0.030 |
Why?
| | DNA Mutational Analysis | 2 | 2007 | 175 | 0.030 |
Why?
| | Time Factors | 1 | 2021 | 2903 | 0.030 |
Why?
| | Glucose | 1 | 2016 | 344 | 0.030 |
Why?
| | Sequence Analysis, DNA | 2 | 2007 | 237 | 0.030 |
Why?
| | DNA Primers | 1 | 2014 | 207 | 0.030 |
Why?
| | Adolescent | 2 | 2021 | 6356 | 0.030 |
Why?
| | Mice, 129 Strain | 1 | 2013 | 38 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2014 | 181 | 0.030 |
Why?
| | Gene Knockout Techniques | 1 | 2013 | 40 | 0.030 |
Why?
| | Pregnancy | 1 | 2021 | 2607 | 0.030 |
Why?
| | Mice, Mutant Strains | 1 | 2012 | 71 | 0.030 |
Why?
| | RANK Ligand | 1 | 2014 | 179 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2014 | 562 | 0.030 |
Why?
| | Blotting, Western | 1 | 2014 | 601 | 0.030 |
Why?
| | Adiposity | 1 | 2013 | 127 | 0.030 |
Why?
| | MAP Kinase Kinase 4 | 1 | 2011 | 29 | 0.020 |
Why?
| | Bone Marrow | 1 | 2013 | 362 | 0.020 |
Why?
| | Young Adult | 1 | 2021 | 3958 | 0.020 |
Why?
| | United States | 1 | 2022 | 4860 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2011 | 157 | 0.020 |
Why?
| | beta Catenin | 1 | 2011 | 102 | 0.020 |
Why?
| | Oxidants | 1 | 2010 | 53 | 0.020 |
Why?
| | Smad1 Protein | 1 | 2010 | 5 | 0.020 |
Why?
| | Glutathione Reductase | 1 | 2010 | 14 | 0.020 |
Why?
| | Chimera | 1 | 2010 | 9 | 0.020 |
Why?
| | omega-N-Methylarginine | 1 | 2009 | 3 | 0.020 |
Why?
| | Biological Factors | 1 | 2009 | 10 | 0.020 |
Why?
| | Ascorbic Acid | 1 | 2009 | 24 | 0.020 |
Why?
| | Gene Targeting | 1 | 2010 | 29 | 0.020 |
Why?
| | Bone Morphogenetic Protein 2 | 1 | 2010 | 46 | 0.020 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 83 | 0.020 |
Why?
| | Organ Specificity | 1 | 2010 | 108 | 0.020 |
Why?
| | Ovariectomy | 1 | 2010 | 119 | 0.020 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 1 | 2009 | 74 | 0.020 |
Why?
| | Validation Studies as Topic | 1 | 2009 | 10 | 0.020 |
Why?
| | Cell Count | 1 | 2009 | 147 | 0.020 |
Why?
| | Aldehydes | 1 | 2009 | 83 | 0.020 |
Why?
| | Vasodilation | 1 | 2009 | 96 | 0.020 |
Why?
| | Bone Marrow Cells | 1 | 2010 | 191 | 0.020 |
Why?
| | Cattle | 1 | 2009 | 210 | 0.020 |
Why?
| | Italy | 1 | 2008 | 26 | 0.020 |
Why?
| | RNA Splice Sites | 1 | 2008 | 10 | 0.020 |
Why?
| | Alleles | 1 | 2009 | 250 | 0.020 |
Why?
| | Microscopy, Confocal | 1 | 2008 | 88 | 0.020 |
Why?
| | Antioxidants | 1 | 2010 | 249 | 0.020 |
Why?
| | Mutation | 2 | 2006 | 1294 | 0.020 |
Why?
| | Endothelium, Vascular | 1 | 2009 | 252 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2008 | 162 | 0.020 |
Why?
| | Cell Survival | 1 | 2009 | 600 | 0.020 |
Why?
| | Cyclin D1 | 1 | 2007 | 56 | 0.020 |
Why?
| | Macrophages | 1 | 2010 | 363 | 0.020 |
Why?
| | DNA, Neoplasm | 1 | 2007 | 147 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2010 | 1105 | 0.020 |
Why?
| | Prevalence | 1 | 2009 | 944 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2009 | 1131 | 0.020 |
Why?
| | Pedigree | 1 | 2006 | 125 | 0.020 |
Why?
| | Hyperplasia | 1 | 2006 | 96 | 0.020 |
Why?
| | Algorithms | 1 | 2009 | 615 | 0.020 |
Why?
| | Liver Function Tests | 1 | 2005 | 47 | 0.020 |
Why?
| | Methylprednisolone | 1 | 2005 | 38 | 0.020 |
Why?
| | Prednisone | 1 | 2005 | 99 | 0.020 |
Why?
| | Base Sequence | 1 | 2006 | 643 | 0.020 |
Why?
| | Remission, Spontaneous | 1 | 2004 | 25 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2007 | 903 | 0.010 |
Why?
| | Lymphocytes | 1 | 2005 | 152 | 0.010 |
Why?
| | Iodides | 1 | 2003 | 2 | 0.010 |
Why?
| | Anti-Inflammatory Agents | 1 | 2005 | 161 | 0.010 |
Why?
| | Introns | 1 | 2003 | 48 | 0.010 |
Why?
| | Neck | 1 | 2004 | 99 | 0.010 |
Why?
| | Heterozygote | 1 | 2003 | 81 | 0.010 |
Why?
| | Exons | 1 | 2003 | 95 | 0.010 |
Why?
| | Thyroid Gland | 1 | 2003 | 73 | 0.010 |
Why?
| | Luminescent Measurements | 1 | 2002 | 15 | 0.010 |
Why?
| | Microsatellite Repeats | 1 | 2002 | 37 | 0.010 |
Why?
| | Family | 1 | 2003 | 170 | 0.010 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 2002 | 54 | 0.010 |
Why?
| | Monitoring, Intraoperative | 1 | 2002 | 54 | 0.010 |
Why?
| | Body Mass Index | 1 | 2005 | 652 | 0.010 |
Why?
| | Pain | 1 | 2004 | 379 | 0.010 |
Why?
| | Liver | 1 | 2005 | 1115 | 0.010 |
Why?
|
|
Ambrogini's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|